List of Excipients in Branded Drug MEMBRANEBLUE

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Dutch Ophthalmic Research Center (International) BV	MEMBRANEBLUE	trypan blue	68803-672	SODIUM CHLORIDE
Dutch Ophthalmic Research Center (International) BV	MEMBRANEBLUE	trypan blue	68803-672	SODIUM PHOSPHATE, DIBASIC, DIHYDRATE
Dutch Ophthalmic Research Center (International) BV	MEMBRANEBLUE	trypan blue	68803-672	SODIUM PHOSPHATE, MONOBASIC, DIHYDRATE
Dutch Ophthalmic Research Center (International) BV	MEMBRANEBLUE	trypan blue	68803-672	WATER

MembraneBlue Excipient Strategy and Commercial Opportunities

Last updated: August 9, 2026

MembraneBlue is a sterile ophthalmic trypan blue product used to stain the anterior lens capsule during cataract surgery. Its commercial value is driven less by the active ingredient, which is widely available, than by sterility, ocular tolerability, packaging, surgeon workflow, and distribution through ophthalmic-surgery channels. The strongest opportunity is a differentiated, ready-to-use capsule-staining platform with improved visualization, lower preparation burden, and validated compatibility with modern cataract procedures.

What is MembraneBlue and how is it used?

MembraneBlue contains trypan blue at 0.15% for ophthalmic surgical staining. The FDA-approved indication is staining the anterior capsule during cataract surgery to improve visualization during capsulorhexis formation, particularly when the red reflex is poor. The product is administered intraocularly during surgery and is removed or exchanged as part of the surgical procedure.[1]

Attribute	MembraneBlue
Active ingredient	Trypan blue
Concentration	0.15%, or 1.5 mg/mL
Dosage form	Sterile ophthalmic solution
Clinical use	Anterior capsule staining during cataract surgery
Route	Intraocular use during surgery
Primary customer	Cataract surgeons, ambulatory surgery centers, hospitals
Therapeutic category	Ophthalmic surgical adjunct
Primary commercial competitor	Other trypan blue capsule-staining products and compounded preparations
Biosimilar relevance	None
Generic pathway	Potentially relevant if marketed as a drug and supported by an applicable ANDA pathway

The product competes in a procedural market rather than a chronic-prescription market. Purchase decisions depend on surgical efficiency, product availability, ease of delivery, and perceived safety more than on long-term patient adherence.

What excipients are used in MembraneBlue?

Public product information identifies a simple aqueous formulation containing trypan blue, sodium chloride, phosphate buffering components, and water for injection.[1] Exact excipient concentrations should be taken from the current approved labeling and manufacturing dossier before formulation replication or regulatory submission.

Formulation function	Likely or reported component	Commercial purpose
Active dye	Trypan blue	Capsule visualization
Tonicity control	Sodium chloride	Reduces osmotic stress on intraocular tissues
Buffering	Monobasic and dibasic phosphate salts	Controls pH during shelf life and use
Vehicle	Water for injection	Sterile parenteral-quality aqueous medium

This excipient profile is strategically important because it is conventional, low-cost, and difficult to differentiate by composition alone. The commercial barriers are more likely to arise from sterile manufacturing, container closure, ophthalmic biocompatibility, color consistency, particulate control, stability, and regulatory documentation.

What formulation attributes matter most?

A competing formulation should target the following specifications:

1. Physiologic or near-physiologic osmolality. Extreme osmolality can increase the risk of corneal endothelial or other intraocular tissue irritation.
2. Controlled pH. The formulation must maintain dye stability without creating an unacceptable ocular pH.
3. Low particulate burden. Intraocular products face stringent particulate and sterility expectations.
4. Consistent staining intensity. Surgeons need predictable visualization across lots.
5. Minimal residual toxicity. The product should be compatible with corneal endothelium, lens structures, and anterior-segment tissues.
6. Single-use presentation. Aseptic handling and contamination control favor prefilled or ready-to-use formats.
7. Low adsorption to packaging. Dyes can interact with polymers, elastomers, glass surfaces, and closure components.

A formulation developer should avoid unnecessary surfactants, preservatives, viscosity enhancers, or complex excipient systems unless they provide a measurable surgical benefit. Intraocular use creates a narrow tolerability window.

How can excipients create commercial differentiation?

The core sodium chloride-phosphate-water system is unlikely to support durable premium pricing. Differentiation is more credible in delivery, handling, stability, and procedure-specific performance.

Viscosity-modified formulations

A modest increase in viscosity could improve retention on the anterior capsule and reduce rapid dispersion into the anterior chamber. Potential excipients include ophthalmic-grade cellulose derivatives or hyaluronic-acid-based polymers. The tradeoff is increased risk of:

• Residual material after irrigation;
• Elevated intraocular pressure;
• More difficult aspiration;
• Interactions with ophthalmic viscosurgical devices;
• Additional toxicology and compatibility requirements.

A viscous product could be positioned for mature cataracts, white cataracts, intumescent lenses, or cases with weak capsule visualization. The formulation would need comparative evidence showing better staining or reduced surgical time.

Buffered low-toxicity systems

An optimized phosphate or alternative buffer system could improve pH stability and reduce lot-to-lot variation. This is more likely to produce an incremental quality advantage than a strong patent moat. The value would come from manufacturing robustness, reduced degradation, and surgeon confidence.

Dual-function dye and viscoelastic products

A product combining trypan blue with a viscoelastic component could reduce the number of intraoperative steps. This approach could compete with separate administration of dye and ophthalmic viscosurgical device products.

The risks are substantial. A combined product may require:

• New stability studies;
• Intraocular compatibility testing;
• Expanded clinical evaluation;
• Assessment of dye-polymer interaction;
• Evaluation of removal characteristics;
• More complex regulatory classification.

The opportunity is strongest where the combined product reduces operating-room time or simplifies preparation.

Low-volume delivery systems

A prefilled syringe, unit-dose ampoule, or controlled micro-volume applicator could provide greater differentiation than a new buffer system. Potential commercial advantages include:

• Lower waste;
• Reduced contamination risk;
• Faster case preparation;
• More consistent dosing;
• Lower risk of accidental overdelivery;
• Better integration with ambulatory surgery center workflows.

Device-related intellectual property may offer stronger protection than the dye formulation itself. A delivery system can also support premium pricing without requiring a new active ingredient.

What patent protection covers MembraneBlue?

The principal patent risk is unlikely to come from the basic trypan blue formulation. Trypan blue is an established dye, and aqueous buffered solutions containing sodium chloride and phosphate salts are conventional pharmaceutical formulations.

IP category	Expected protection strength	Commercial assessment
Basic trypan blue composition	Low	Easy to design around; limited novelty
0.15% concentration alone	Low to moderate	Concentration may be relevant but is vulnerable to obviousness and prior-art challenges
pH and osmolality ranges	Moderate	Potentially useful if tied to demonstrated ocular tolerability or stability
Viscosity-enhanced formulation	Moderate	Stronger if supported by unexpected staining or safety data
Prefilled delivery system	Moderate to high	Can provide device and combination-product protection
Specific capsule-staining method	Moderate	May support method-of-use claims, subject to prior art and enforceability
Manufacturing and sterility controls	Moderate	Often difficult to enforce against competitors but useful operationally
Brand and surgeon adoption	High commercially, not patent-based	Important barrier to substitution

No reliable conclusion should be drawn that a specific patent protects MembraneBlue without a current patent-family, assignment, maintenance, and litigation review. FDA labeling and the Orange Book do not provide a complete worldwide patent history. A commercial diligence review should distinguish patents owned by the product sponsor from patents covering broader trypan blue ophthalmic technologies.

What is the Orange Book status of MembraneBlue?

MembraneBlue’s regulatory status must be assessed through the current FDA Drugs@FDA database and Orange Book rather than through product branding alone.[2] If the product has an approved drug application and listed patents or exclusivity, those entries would determine whether an ANDA applicant could face Paragraph IV requirements.

The relevant regulatory questions are:

• Whether MembraneBlue has an active FDA application;
• Whether the application is classified as an NDA or another pathway;
• Whether the product is currently marketed;
• Whether any patents are listed in the Orange Book;
• Whether pediatric or other statutory exclusivity remains active;
• Whether a proposed competitor can use an ANDA, 505(b)(2), or another pathway.

A competitor should not assume that absence of a prominent Orange Book listing eliminates all IP risk. Unlisted formulation, process, device, trademark, trade-secret, and foreign patents can still affect market entry.

When does MembraneBlue lose exclusivity?

The active-ingredient and basic formulation exclusivity position is likely mature. Trypan blue has been used in ophthalmology for many years, and the key commercial question is not chemical novelty but the remaining enforceability of any product-specific patents, regulatory exclusivity, and market authorization.

Exclusivity type	Relevance to MembraneBlue	Strategic implication
New chemical entity exclusivity	Unlikely to be commercially material for established trypan blue	Does not create a durable barrier
Five-year NCE exclusivity	Depends on original FDA classification and approval history	Must be verified from FDA records
Three-year clinical-investigation exclusivity	Possible only for qualifying new clinical work	Could delay certain applications, not necessarily all competition
Orphan exclusivity	Not expected for cataract capsule staining	No apparent orphan-market protection
Patent exclusivity	Depends on specific listed and unlisted families	Requires current patent search
Trademark protection	Brand-specific	Can block confusingly similar branding but not generic entry
Trade secrets	Manufacturing and quality systems	May slow replication without preventing competition

What Paragraph IV challenges and generic entry risks exist?

A Paragraph IV challenge is relevant only if a competitor files an ANDA referencing a listed drug and certifies that an Orange Book patent is invalid, unenforceable, or not infringed.[3] For MembraneBlue, the economic attractiveness of an ANDA depends on market size, reimbursement, manufacturing cost, and the availability of an approved reference product.

Generic launch scenarios

Scenario 1: No meaningful listed patent barrier

A competitor could enter after completing pharmaceutical equivalence, sterility, stability, and bioequivalence or suitability work appropriate to the product. Price competition would likely be strongest in hospital and ambulatory-surgery-center purchasing contracts.

Scenario 2: Formulation patent remains listed

The competitor could challenge the patent under Paragraph IV, wait for expiration, or pursue a non-infringing formulation. A simple change to buffer, pH, packaging, or concentration may create regulatory complications if the product no longer qualifies for an uncomplicated ANDA.

Scenario 3: 505(b)(2) development

A 505(b)(2) applicant could rely partly on existing literature or FDA findings while pursuing a differentiated formulation, delivery system, or indication. This route is more plausible for a viscosity-modified or combination product than for a simple copy.

Scenario 4: Device-led competition

A company could commercialize a novel applicator or prefilled system with trypan blue as part of a combination product. This could avoid direct price comparison with a conventional vial but would create additional combination-product and device obligations.

Which companies compete with or could challenge MembraneBlue?

The competitive field includes:

• Branded ophthalmic surgical-dye suppliers;
• Manufacturers of trypan blue ophthalmic solutions;
• Contract manufacturers supplying sterile intraocular products;
• Compounding pharmacies serving ophthalmic surgery;
• Suppliers of ophthalmic viscosurgical devices that could add capsule-staining functionality;
• Surgical-device companies developing integrated cataract-delivery systems.

The most credible challengers are companies with existing sterile ophthalmic manufacturing, cataract-surgery sales forces, and hospital contracting capabilities. A low-cost pharmaceutical manufacturer without ophthalmic distribution may obtain approval but still struggle to displace an established product.

How does MembraneBlue compare with alternative capsule-staining products?

Criterion	MembraneBlue-type product	Alternative trypan blue product	Compounded preparation
Ready-to-use status	Usually high	Depends on supplier	Variable
Sterility assurance	Validated commercial process	Depends on manufacturer	Depends on compounding controls
Cost	Premium to bulk dye	May be lower	Potentially lowest
Regulatory support	Stronger for approved product	Depends on approval	More limited
Formulation flexibility	Limited by approved composition	Variable	High
Hospital procurement	Favorable if contracted	Depends on supply	Often less favorable
IP exposure	Product- and formulation-specific	Product-specific	Usually low patent exposure
Supply-chain resilience	Depends on sponsor	Depends on supplier	Often variable

The main differentiation axis is operational reliability. Surgeons and facilities have limited tolerance for product shortages, inconsistent staining, or difficult preparation.

What licensing opportunities exist for MembraneBlue-related technology?

Licensing opportunities are more likely to involve platform improvements than the legacy dye itself.

Attractive licensing targets

• Prefilled intraocular delivery devices;
• Unit-dose sterile ampoules;
• Viscosity-controlled capsule-staining formulations;
• Stabilized dye systems with extended shelf life;
• Combination products integrating dye and ophthalmic viscoelastic;
• Manufacturing processes that reduce dye adsorption or particulate formation;
• International distribution rights in cataract-growth markets;
• Co-development with ophthalmic surgery companies.

A licensing deal should allocate ownership of formulation patents, device patents, regulatory data, manufacturing know-how, field restrictions, and rights to improvements. A formulation license without control of the delivery device may provide limited differentiation.

What manufacturing and geographic barriers affect commercial entry?

The key manufacturing barriers are aseptic processing, validated sterilization strategy, container-closure integrity, particulate control, dye assay uniformity, extractables and leachables, and stability under transport conditions.

Geographic opportunity is strongest in markets with high cataract volumes and growing ambulatory surgery capacity. Commercial expansion requires country-specific assessment of:

• Drug versus medical-device classification;
• Import and local manufacturing requirements;
• Registration of sterile ophthalmic products;
• Procurement rules;
• Surgeon preference;
• Reimbursement;
• Availability of approved alternatives;
• Patent and trademark status.

A manufacturer can reduce entry risk by using a globally scalable formulation and a locally adaptable packaging configuration.

What revenue exposure and commercial upside does the product have?

MembraneBlue is a procedure-linked product with modest unit volume but recurring use across high-volume cataract centers. Revenue exposure is sensitive to:

• Annual cataract surgery volumes;
• Product price per case;
• Share of surgeries involving poor red reflex or difficult visualization;
• Hospital purchasing contracts;
• Generic and compounded alternatives;
• Supply interruptions;
• Adoption of alternative staining technologies.

The strongest commercial model is not a standalone dye sale. It is a cataract-surgery workflow platform that combines the dye, delivery device, and procurement support. A premium product needs evidence of reduced preparation time, lower waste, improved staining consistency, or better handling in complex cataract cases.

Key Takeaways

• MembraneBlue is a 0.15% trypan blue sterile ophthalmic surgical product for anterior capsule staining during cataract surgery.
• Its conventional excipient system offers limited composition-based differentiation.
• The strongest opportunities are viscosity optimization, improved stability, prefilled delivery, unit-dose packaging, and combination products.
• Biosimilar risk does not apply because MembraneBlue is a small-molecule ophthalmic product, not a biologic.
• Generic risk depends on FDA application status, Orange Book listings, remaining patents, and the feasibility of an ANDA or 505(b)(2) pathway.
• Device and formulation patents may provide stronger future protection than claims directed only to trypan blue concentration.
• Commercial success depends on sterile manufacturing, surgeon workflow, supply reliability, and cataract-surgery distribution.
• Licensing value is highest in delivery systems, combination formulations, manufacturing know-how, and regional commercialization rights.

FAQs

Is MembraneBlue a biologic or biosimilar product?

No. MembraneBlue contains the small-molecule dye trypan blue. Biosimilar pathways do not apply.

Can a competitor market a lower-cost trypan blue product?

Potentially. A competitor would need to satisfy the applicable FDA approval pathway, sterile ophthalmic quality requirements, and any remaining patent or exclusivity restrictions.

Are phosphate buffers suitable for intraocular products?

They can be suitable when the final formulation meets pH, osmolality, sterility, stability, and ocular-tolerability requirements. Buffer selection must be validated in the complete formulation.

Could hyaluronic acid improve MembraneBlue?

It could improve retention or handling, but it would also increase formulation complexity and require evaluation of residual material, pressure effects, dye compatibility, and removal during surgery.

What is the most defensible new product strategy?

A ready-to-use, prefilled, low-volume delivery system with validated staining consistency and a formulation optimized for difficult cataract cases offers the clearest path to differentiation.

References

1. U.S. Food and Drug Administration. (n.d.). MembraneBlue 0.15% trypan blue ophthalmic solution: Prescribing information.
2. U.S. Food and Drug Administration. (n.d.). Drugs@FDA and Approved Drug Products with Therapeutic Equivalence Evaluations.
3. U.S. Food and Drug Administration. (n.d.). Abbreviated new drug application submissions: Content and format of an ANDA.